EUCTR2012-003076-39-BG进行中（未招募）不适用
A randomized, double blind study comparing BF2.649 (Pitolisant) to placebo in two parallel groups on the weekly frequency of cataplexy attacks and Excessive Daytime Sleepiness in narcoleptic patients with cataplexy - NA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Bioprojet
- 入组人数
- 147
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men or women, of 18 years of age and over.
- •Patients with a diagnosis of narcolepsy with cataplexy according to the International Classification of Sleep Disorders (ICSD-2) criteria
- •De novo” patients, or patients treated by purported anticataplectic drugs, i.e. SSRIs and patients treated by sodium oxybate at stable dose, for a minimum period of one month, having shown an incidence of at least 3 weekly cataplexy attacks and with an ESS score = 12
- •Patients should be free of prohibited treatments (see p.10) or have discontinued them for at least 7 days at the start of baseline period.
- •Women of child-bearing potential must use a medically accepted effective, method of birth control, estimated efficient enough by the investigator, and agree to continue this method for the duration of the study and the month following treatment discontinuation. Women must be negative to serum pregnancy test performed at the screening visit and should not be breast-feeding patients.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 137
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Patients with any other conditions that can be considered the primary causes of EDS: such as sleep related breathing disorders as defined by a sleep Apnea Index = 10 per hour or and an Apnea/Hypopnea Index = 15 per hour, periodic limbs movement (PLM) disorders as defined by a PLM arousal index (PLMAI) = 10 per hour, shift work, chronic sleep deprivation, circadian sleep wake rhythm disorder or any other medical or neurological causes that could account for narcolepsy symptoms associated with EDS.
- •Psychiatric and neurological disorders, other than narcolepsy/cataplexy, such as moderate or severe psychosis or dementia, bipolar illness, severe anxiety, clinical severe depression (BDI = 16) with suicidal risk (item G BDI > 0), or depression treated for less than 8 weeks, history of seizure disorder or other problem that, in the investigator’s opinion, would preclude the patient’s participation and completion of this trial.
- •Patients unable or unwilling to temporarily suppress non-authorized drugs during the study.
- •Concurrent use of hypnotics, tranquilizers, sedating antihistamines, benzodiazepines, anticonvulsants, psychostimulants, (amphetamines, amphetamine-like, modafinil, methylphenidrate, or other CNS stimulants), tricyclic antidepressants (e.g. imipramine), clonidine will not be accepted since 3 weeks before randomisation and during study.
- •Current or recent (within one year) history of a substance abuse or dependence disorder including alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- •Other active clinically significant illness, including unstable cardiovascular, or neoplasic pathology which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise the study participation.
- •Patients with a known history of long QTc syndrome (e.g. syncope or arrhythmia) or presenting any significant serious abnormality of the ECG (e.g. recent myocardial infarction), or QTc Fridericia higher than 450 ms for male and 470ms for female
- •(electrocardiogram Fridericia’s corrected QT interval =QT / 3 (cube root) RR)
- •Patients with Severe Hepatic Impairment or with Severe Renal Impairment, or with any other significant abnormality in the physical examination or clinical laboratory results.
- •Known hypersensitivity to the tested treatment including active substance and excipients.
- •Prior severe adverse reactions to CNS stimulants
- •Any patients presenting congenital galactosemia, glucose-galactose malabsorption or lactase deficiency due to the presence of lactose in investigational treatments
- •Patients participating in another study, or having participated in a study during the previous month
研究者
相似试验
进行中（未招募）
不适用
Aarcolepsy with CataplexyMedDRA version: 16.0Level: LLTClassification code 10028715Term: Narcolepsy with cataplexySystem Organ Class: 100000004852EUCTR2012-003076-39-CZBioprojet148
进行中（未招募）
1 期
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaEUCTR2012-003524-21-GBMedImmune, LLC564
进行中（未招募）
1 期
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaCTIS2024-511841-20-00AstraZeneca AB223
已完成
2 期
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesotheliomainoperabel maligne mesothelioomPleural or Peritoneal MesotheliomaNL-OMON41613Medimmune LLC, subsidiary of AstraZeneca32
进行中（未招募）
不适用
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaEUCTR2012-003524-21-NLMedImmune, LLC564